Malt-1 inhibitor for the treatment of allergic inflamation

GR20250100040APending Publication Date: 2026-08-12CLOUDPHARM PRIVATE CO +1
6 Cites 0 Cited by

Patent Information

Application Number
GR20250100040
Authority / Receiving Office
GR · GR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-01-20
Publication Date
2026-08-12
Patent Text Reader

Abstract

Novelty: a) a pharmaceutical composition including a compound selected from the group consisting of gliptins, their pharmaceutically acceptable salts, and their hybrids is disclosed; b) use of gliptins as allosteric inhibitors of MALT1 for treating allergic inflammatory disease. Purpose: use in a therapeutic or prophylactic method of treating allergic inflammatory diseases in subjects, preferably human subjects in need.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Application of sitagliptin phosphate

    CN115671109A

  • Decreasing immune activity through modulation of postcellular signaling factors

    WO2019241746A1

  • Methods and compositions for modulating immune dysregulation

    WO2020150606A1

  • Treatment of dermatological conditions

    WO2022074228A1

  • Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases

    WO2022155674A1